This article consists of 10 pages and 2245 words. In order to have full access to this article, email us at thedocumentco@hotmail.co.uk
Content:
| 1 | Introduction | 2 |
| 2 | Phase 1 Trial | 3 |
| 3 | Phase 1b Trial | 3 |
| 4 | Phase II Trial | 4 |
| 5 | Conclusion | 4 |
| 6 | References | 5 |
Introduction:
There has been constant research in the treatment of anxiety and it has finally led the medicine specialists and the biochemists to something special and of real value. BNC210 is high quality compound to modify the brain activity.
It doesn’t only reduce the anxiety, it cures it hence it’s not just a medicine but a full-fledged treatment and it is without any major side effects like memory loss. Like various anxiety drugs, like Valium, it has no side effects.
The mechanism of the drug is easy and simple to understand. It targets alpha 7 nicotine acetyl-choline receptor and by negative allosteric modulation, helps reduction of anxiety and its treatment.
The Managing Director and CEO of Bionomics, DR. Deborah has given a good news for the people who suffer from anxiety and want a permanent cure for it, in terms of BNC210 because according to her, it is going make their lives a lot easier.
She also added that it is possible to reduce the consumption of social and healthcare resources if there is a constant and effective management of anxiety.
WHAT IS ANXIETY
Anxiety is a medical condition which involves feeling anxious for long periods of time and it can get worse over time. This condition disrupts the normal daily activities of the person and becomes a hindrance in school work, office performance and relationships.
According to the National Institute of Mental Health, (2013), the various types of anxiety include post-traumatic stress disorder, generalized anxiety disorder, various kind of phobias and panic disorder. In
Australia, a careful estimate indicates that as much as 14.4% of the entire population suffers from one or the other type of anxiety. In US alone, there are more than 40 million patients of anxiety disorders and in some instances, it was discovered that people suffered more than one type of anxiety disorder.
There is a huge array of drugs available in the market which are consumed to treat anxiety related disorders including benzodiazepines SRRIs and SNRIs. The problem with these drugs, however, is that they limit the efficacy, late onset of action and many other side effects (Siegel and Mathews, 2015).
Almost all current anti-anxiety medications have severe side effects which exacerbate the condition of the patients.BNC210 – Anxiolytic Drug. Side effects include memory loss, lack of energy, disorientation and confusion, drowsiness, slow reflexes as well as depression (Edwards, 1981).
Generalised Anxiety Disorder (GAD)
Generalised Anxiety Disorder (GAD) is a type of anxiety related medical condition which is characterised by excessive worrying and feelings of dread, sadness and worry for at least six months or more. This disorder can have emotional as well as physical symptoms.
Emotional symptoms include paranoia which is not specifically associated with anything therefore it is termed as generalised anxiety disorder (US National Library of Medicine, 2015). GAD is two times more common in females than it is in males.
It causes irritability, sleep disturbances, dry mouth, sweating, mood swings and restlessness. These are collectively known as symptoms of generalised anxiety disorder as opposed to being treated as independent symptoms.
BNC210 – Anxiolytic Drug. The intervention for GAD most often does not result in complete resolution of the symptoms but in short term psychological therapies such as behaviour management and pharmacological treatments especially selective serotonin reuptake inhibitors (SSRIs) are used (Gale and Davidson, 2007) as well as serotonin-norepinephrine reuptake inhibitor (SNRI).
Until the mid 1980’s, benzodiazapines were the only available treatment option for GAD and other anxiety conditions. But it was seen that benzodiazapines had severe side effects such has high tolerance and dependence.
Psychotherapy is also used in the treatment of GAD adjunct to medicinal treatment however there are some newly discovered compounds which are in early stages of trials and these new treatments are expected to cause less severe side effects in the future (Reinhold and Rickels, 2015).
ABOUT BIONOMICS LIMITED
Bionomics is an innovative company which is destined to create wonders in the field of biopharmaceutical. It is working on the development of therapeutics for cancer and diseases of central nervous system.
The areas that Bionomics is currently working on include pain, memory loss, cancer and anxiety, which is done by their small molecule product development section. The oncology approach that Bionomics has opted is the cancer stem cells therapeutics.
Discovering new drugs is a very expensive process and in order to produce an effective drug, the companies require large amounts of capital investment.
BNC210 Anxiolytic Drug
BNC210 is an upcoming drug by an Australian biopharmaceutical company known as Bionomics Limited. It is widely acknowledged that the aim of Bionomics Limited is to discover and develop constantly in orthodox and unconventional ways simultaneously to find effective and innovative therapeutics for the diseases of central nervous system and cancer.
The phase one of BNC210 which is the multiple ascending dose, placebo clinical trial has been clear which is again a good news for the sufferers of anxiety disorder.
BNC210 is a novel small molecular drug which is a highly selective and specific at the receptor it works. It is an oral drug to treat anxiety and depression. For alpha-7 nicotinic acetylcholine receptor, also called the alpha-7receptor, it works as a negative allosteric modulator which is the mechanism of its function.
There is clear association between the symptoms of anxiety and the alpha-7 receptors and acetylcholine. Some evidence shows that BNC210 enables the growth of neurite like axons and dendrites which will further help in cognitive development.
This drug promises to be free from significant side effects of the present day anti-anxiety medications such as sedation, impairment of memory and addiction (Bionomics Limited, 2015). BNC210 is L-Isoleucyl-L-tryptophan which is a dipeptide consisting of the amino acids isoleucine and typtophan. This means that the drug will have a relatively shorter half-life as compared to SSRIs….
Recent Comments